European researchers are putting finishing touches on the first-ever clinical guideline for drug treatment of multiple sclerosis, with a preview presented at ECTRIMS in advance of its final release.
The guideline will discuss the considerations involved with each of the dozen available drugs but with little specific advice on how to choose among them, said Susana Otero-Romero, MD, of the Multiple Sclerosis Center of Catalonia in Barcelona, speaking at the European Committee for Treatment and Research in Multiple Sclerosis meeting.
Selecting a drug will depend on patient characteristics, disease severity, drug safety profile, and accessibility – in combination with a conversation with the patient about their preferences, she said.
"The evidence thus far does not allow us to prioritise drugs," Otero-Romero told MedPage Today. "We're lacking head-to-head comparisons."
The guideline was developed jointly by ECTRIMS and the European Academy of Neurology, via a committee chaired by Xavier Montalban, MD, of Vall d'Hebron Hospital in Barcelona, and Ralf Gold, MD, of Ruhr University Bochem in Germany, and coordinated by Otero-Romero, and follows the GRADE methodology for assessing evidence.
There are currently no other comprehensive guidelines for MS treatment, Otero-Romero said. There has only been some consensus on specific topics like treatment of attacks, and the use of particular treatments like mitoxantrone and natalizumab.
The American Academy of Neurology is taking comments on a draft version of its evidence-based guidelines for MS disease-modifying therapies through Oct. 8.
Co-authors disclosed financial relationships with several MS drug makers.
Source: MedPage Today, 19/09/16, By Kristina Fiore, Associate Editor
Primary Source: ECTRIMS
Source Reference: Otero-Romero S, et al "ECTRIMS-EAN clinical practice guideline on pharmacologic management of multiple sclerosis" ECTRIMS 2016; Abstract 255.